Recursion Pharmaceuticals

Recursion Pharmaceuticals

Yahoo Finance • 6 days ago

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (NASDAQ:MRNA) and Recursion Pharmaceuticals (NASDAQ:RXRX... Full story

Yahoo Finance • 9 days ago

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candi... Full story

Yahoo Finance • 12 days ago

Cathie Wood buys $11.5 million of battered tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story

Yahoo Finance • 12 days ago

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Key Points Artificial intelligence technology giant Nvidia owns a handful of promising stocks. One of these holdings is helping lead the charge of change for an industry that could use a cost-reducing revamp. Although this name poses abov... Full story

Yahoo Finance • 13 days ago

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying

Key Points Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds. 10 stocks we like better than Recursion Pharmaceutica... Full story

Yahoo Finance • last month

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion'... Full story

Yahoo Finance • last month

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?

Key Points Recursion Pharmaceuticals is using AI to improve how we develop drugs. The company has partnered with several major corporations in this quest. The biotech has yet to show meaningful results from its approach. 10 stocks we lik... Full story

Yahoo Finance • 2 months ago

The Future of Intoxication Detection May Be in Your Voice

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safe... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right Now

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 2026, highlighted by positive early data... Full story

Yahoo Finance • 2 months ago

Recursion Announces Board Transition

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current te... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working?

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is accelerating its drug development programs and unlocking cost-savings opportunities thanks to i... Full story

Yahoo Finance • 3 months ago

Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to supercharge its AI-driven drug discovery platform through an expanded partnership with Citeline. Citeline is a lead... Full story

Yahoo Finance • 3 months ago

Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX)

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and development platform, aiming to improv... Full story

Yahoo Finance • 3 months ago

1 Beaten-Down AI Stock to Buy and 1 to Avoid

Key Points Alphabet is already a leader in AI and boasts attractive growth avenues beyond this industry. Recursion Pharmaceuticals has a long way to go before demonstrating that its approach works. 10 stocks we like better than Alphabet ›... Full story

Yahoo Finance • 3 months ago

2 AI Healthcare Stocks to Buy Right Now

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily made the world a better place. Indeed, a recent survey from PwC indicates that 56% of CEOs aren't yet seeing any... Full story

Yahoo Finance • 4 months ago

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

The past several weeks have been challenging ones for the overall market. But they've been downright miserable ones for most artificial intelligence (AI) stocks. Microsoft shares are down more than 20% from last year's peak, for instance,... Full story

Yahoo Finance • 4 months ago

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

Key Points In retrospect, it’s clear that most AI stocks’ inflated valuations were never fully justified. The technology isn’t going away, though. It’s evolving into one with more practical and marketable uses. Some companies are better p... Full story

Yahoo Finance • 4 months ago

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Key Points Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.10 s... Full story

Yahoo Finance • 4 months ago

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a let down, big let down. Came on the sh... Full story